Economic impact of biomarker-based aging interventions on healthcare costs and individual value.
- 1enGene, Basel, Switzerland.
Abstract
We investigate the economic impact of controlling the pace of aging through biomarker monitoring and targeted interventions. Using the DunedinPACE epigenetic clock as a measure of biological aging rate, we model how different intervention scenarios affect frailty trajectories and their subsequent influence on healthcare costs, lifespan, and health quality. Our model demonstrates that controlling DunedinPACE from age 50 onward can reduce frailty prevalence, resulting in cumulative healthcare savings of up to CHF 131,608 per person over 40 years in our most optimistic scenario. From an individual perspective, the willingness to pay for such interventions reaches CHF 3.2 million in the most optimistic scenario when accounting for both extended lifespan and improved health quality. When the direct cost of epigenetic testing is included, the healthcare-system case is sensitive to test price and testing frequency, whereas the individual-value case remains strongly positive. These findings suggest substantial economic value in technologies that can monitor and modify biological aging rates, providing evidence for both healthcare systems and consumer-focused business models in longevity medicine.
Related
- scDRP: disentangled representation learning for predicting single-cell responses to perturbations and estimating individual treatment effects
- Selective Phospholipase A2 Gene Expression in Peri-Implantitis: An Intra-Individual Paired Gingival Tissue Study
- Structural diversity of human urinary N-glycans revealed by reversed-phase LC/MS/MS toward a resource for biomarker discovery
- Computational design and molecular dynamics for developing a multistage serodiagnostic biomarker for tuberculosis
- Flow Cytometry and AI-Driven Biomarker Discovery in Acute Kidney Injury: From Mechanistic Insights to Translation Applications in Clinical and Austere Environments
BibTeX
@article{felizzi2026economic,
title = {{Economic impact of biomarker-based aging interventions on healthcare costs and individual value.}},
author = {Federico Felizzi},
journal = {Frontiers in genetics},
year = {2026},
month = oct,
doi = {10.3389/fgene.2026.1814599},
url = {https://europepmc.org/article/MED/42928929},
note = {CC BY},
}
RIS
TY - JOUR
TI - Economic impact of biomarker-based aging interventions on healthcare costs and individual value.
AU - Federico Felizzi
PY - 2026
DA - 2026/10/12
JO - Frontiers in genetics
DO - 10.3389/fgene.2026.1814599
UR - https://europepmc.org/article/MED/42928929
AB - We investigate the economic impact of controlling the pace of aging through biomarker monitoring and targeted interventions. Using the DunedinPACE epigenetic clock as a measure of biological aging rate, we model how different intervention scenarios affect frailty trajectories and their subsequent influence on healthcare costs, lifespan, and health quality. Our model demonstrates that controlling DunedinPACE from age 50 onward can reduce frailty prevalence, resulting in cumulative healthcare savings of up to CHF 131,608 per person over 40 years in our most optimistic scenario. From an individual perspective, the willingness to pay for such interventions reaches CHF 3.2 million in the most optimistic scenario when accounting for both extended lifespan and improved health quality. When the direct cost of epigenetic testing is included, the healthcare-system case is sensitive to test price and testing frequency, whereas the individual-value case remains strongly positive. These findings suggest substantial economic value in technologies that can monitor and modify biological aging rates, providing evidence for both healthcare systems and consumer-focused business models in longevity medicine.
SN - 1664-8021
ER -